Alnylam Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
AMVUTTRA has rapidly gained market share in ATTR cardiomyopathy, driving strong revenue growth and broad physician adoption. Clinical data support its differentiated profile, while strategic investments in diagnosis, access, and innovation position it for sustained leadership and expansion globally.
-
AMVUTTRA's growth is fueled by rising treatment rates and strong market access, with a focus on expanding first-line share and robust revenue guidance through 2030. The pipeline features next-gen TTR therapies, cardiometabolic assets, and bleeding disorder programs, supported by a 30% R&D reinvestment strategy and selective external innovation.
-
Six approved RNAi medicines and a robust pipeline drove 2025 revenues to nearly $3 billion, with Amvuttra leading TTR franchise growth. Ambitious 2030 goals target global TTR leadership, 10+ tissue types, and over $10 billion in annual revenue.
Fiscal Year 2025
-
Blockbuster AMVUTTRA launch drove 81% revenue growth and GAAP profitability in 2025, with strong TTR and rare disease franchise momentum. 2026 guidance projects 71% revenue growth, continued pipeline expansion, and disciplined investment, while pricing and competitive dynamics are factored into outlook.
-
Management highlighted strong Amvuttra launch momentum, broad patient access, and sustainable growth, with new five-year goals to be announced in early 2025. Next-generation therapies and a robust pipeline, including Huntington's and Alzheimer's programs, are set to drive future value.
-
Strong U.S. cardiomyopathy launch drove two guidance upgrades, with balanced first- and second-line growth and broad first-line access. Pipeline advances include next-gen TTR therapies, promising hypertension and CNS programs, and ambitious expansion into new tissues by 2030.
-
Q3 2025 saw 103% year-over-year revenue growth, driven by the U.S. AMVUTTRA® ATTR-CM launch and robust TTR franchise performance. Guidance for 2025 was raised, with ex-U.S. expansion expected in 2026 and continued pipeline advancement in RNAi therapeutics.
-
Strong Q2 performance in the ATTR market drove a major revenue guidance upgrade, with rapid provider and payer access supporting both first and second line growth. The pipeline remains robust, with next-generation products and a major hypertension program advancing, while new five-year strategic goals and increased financial flexibility position the company for continued innovation and expansion.
-
Strong commercial launch of the TTR cardiomyopathy franchise drove a major revenue guidance upgrade, with rapid U.S. formulary access and balanced first- and second-line uptake. Pipeline advances include a third-generation TTR product and a large hypertension study, while strategic focus remains on innovation, AI, and global expansion.
-
Six marketed products and a strong pipeline support long-term growth, with a major focus on the ATTR cardiomyopathy launch and expanding market share. Next-generation therapies and strategic partnerships, such as with Roche for hypertension, position the company for future opportunities.
-
CARDIA 3 results show zilebesiran provides sustained blood pressure reductions, especially in patients on diuretics, with a favorable safety profile. The ZENITH phase III trial will enroll 11,000 high-risk patients to assess cardiovascular outcomes, aiming for top-line results by 2030.
-
The conference highlighted strong early commercial success for AMVUTTRA, rapid provider adoption, and significant growth potential in ATTR cardiomyopathy. The pipeline features innovative programs in hypertension, CAA, diabetes, and obesity, with key data and launches expected through 2026.
-
Q2 net product revenues surged 64% year-over-year to $672 million, driven by the U.S. AMVUTTRA launch for ATTR-CM and robust TTR franchise growth. 2025 revenue guidance was raised by 27% at the midpoint, reflecting strong demand and expanding international launches.
-
European approval for Amvuttra in cardiomyopathy accelerates global TTR franchise expansion, with launches in Japan and Germany planned. Robust pipeline progress includes CNS, hypertension, and metabolic programs, while strong commercial execution and broad market access drive rapid uptake and revenue growth.
-
Early cardiomyopathy launch shows rapid formulary access and broad demand across patient types. Revenue guidance anticipates strong TTR growth, with payer dynamics and compliance programs supporting uptake. Watch for Q2 updates on access, demand, and revenue.
-
Q1 2025 saw 28% revenue growth, led by a 36% increase in the TTR franchise and a strong U.S. launch of Amvuttra for ATTR-CM. Early uptake is robust, with broad payer coverage and rapid formulary inclusion, supporting reiterated full-year guidance and a positive outlook.
-
Modest tariff exposure and regulatory changes are not expected to disrupt growth. 2025 TTR revenue guidance targets 36–41% growth, driven by robust product launches and broad label approvals. Pipeline innovation and value-based agreements support long-term expansion.
-
FDA approved Amvuttra for ATTR cardiomyopathy, making it the only approved therapy for both polyneuropathy and cardiomyopathy. HELIOS-B data showed reduced mortality and hospitalizations, strong safety, and infrequent dosing. Launch ramp is expected in H2 2025, with broad payer access and ongoing innovation.
-
The panel discussed a CNS siRNA pipeline leveraging C16 technology, with lead programs in Alzheimer's, CAA, and Huntington's. Early clinical data show promising biomarker engagement and safety, with long-term studies and additional readouts expected this year. Further advances include Tau and alpha-synuclein programs and ongoing work on systemic CNS delivery.
-
Strong 2024 revenue growth and robust 2025 guidance reflect a thriving RNAi pipeline, with major advances in ATTR amyloidosis, cardiovascular, neuroscience, and metabolic programs. Platform innovation, global expansion, and new manufacturing processes position the company for long-term leadership and sustainable profitability.
-
Strong 2024 performance and robust pipeline position the company for a landmark 2025, with multiple global launches, sustainable profitability, and continued innovation in RNAi therapeutics. ATTR franchise expansion and new CNS programs are key growth drivers.
Fiscal Year 2024
-
Delivered 33% revenue growth in 2024, reaching $1.646B, with strong TTR and rare franchise performance and $95M in non-GAAP operating profit. 2025 guidance projects 31% revenue growth, driven by anticipated Amvuttra label expansion and robust pipeline progress.
-
Strong commercial growth and upgraded guidance were driven by robust TTR franchise performance, even amid new competition. Positive HELIOS-B data supports label expansion, while pipeline advances and strategic partnerships with Roche and Regeneron enable broader market reach and innovation.
-
A leading RNAi platform is driving strong commercial growth with four marketed products and a rich pipeline, including major expansion in TTR cardiomyopathy. Regulatory filings for AMVUTTRA are underway globally, supported by compelling HELIOS-B data, and a robust commercial infrastructure is in place for launch.
-
Strong commercial growth and upgraded guidance set the stage for a major cardiomyopathy launch next year, supported by robust HELIOS-B data and broad payer access expectations. Pipeline momentum continues with key readouts and expansion into new therapeutic areas.
-
Q3 2024 saw 34% year-over-year revenue growth to $420M, driven by strong TTR and rare franchise performance, robust AMVUTTRA uptake, and pipeline advances in CNS and Alzheimer's. Regulatory submissions for vutrisiran and preparations for an ATTR cardiomyopathy launch are underway.
-
Amvuttra is positioned for first-line use in ATTR cardiomyopathy, supported by strong HELIOS-B data, global commercial readiness, and robust patient access. The company targets rapid market expansion, sustainable innovation with next-gen assets, and expects to double its clinical pipeline by 2025.
-
HELIOS-B data showed patisiran significantly reduced all-cause mortality and improved quality of life in TTR cardiomyopathy, positioning it as a potential first-line therapy. The market is large and growing, with robust commercial plans and further updates expected at upcoming events.
-
Vutrisiran's ESC data showed strong mortality benefits and broad efficacy, positioning it for first-line use in cardiomyopathy. The launch is targeted for Q2 2025, with favorable reimbursement dynamics and a significant market opportunity. Pipeline innovation and financial goals remain on track.
-
HELIOS-B phase 3 results show vutrisiran significantly reduced mortality and cardiovascular events in ATTR cardiomyopathy, with robust benefits across all subgroups and strong safety. Functional capacity and quality of life were preserved, supporting potential first-line and combination use.
-
Q2 2024 saw 34% year-over-year revenue growth to $410M, driven by strong TTR and rare disease franchises. Positive HELIOS-B phase III results for vutrisiran in ATTR cardiomyopathy led to raised 2024 guidance and launch preparations for 2025.
-
HELIOS-B Phase III results show vutrisiran met all primary and secondary endpoints, significantly reducing mortality and cardiovascular events in ATTR amyloidosis with cardiomyopathy. Benefits were consistent across subgroups, including those on tafamidis, with a strong safety profile.